AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02434770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2
Description: Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
Study NCT02027831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Study NCT02183168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam suppository
Study NCT01231919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO
Study NCT01231919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT01231919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03356275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for Resilience in Illness: Support for Parents
Description: Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
Study NCT02336230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remestemcel-L
Description: Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
Study NCT04252131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cassia seed tablet
Description: traditional Chinese herbs
Study NCT04252131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cassia seed tablet
Description: traditional Chinese herbs
Study NCT02172638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-Track Protocol
Study NCT02172638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual management
Study NCT02463279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinusys Dilation System
Description: Dilation of frontal recess and/or sphenoid sinus ostia
Study NCT02183168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam tablet
Study NCT02183168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Study NCT03645733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower Temperature Group
Description: Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
Study NCT03740659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin + Dexamethasone
Description: Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
Study NCT03289182 — intervention group
Intervention type: DRUG
Intervention: MabThera
Description: Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT00940446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insorb staples
Description: absorbable staples required for wound closure
Study NCT00940446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metal staples (Ethicon metal stapler)
Description: wound closure with metal staples
Study NCT04734366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine closure with Baseball suture technique
Description: A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision.
Study NCT04734366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Layer Continuous Locked
Description: Suturing is continued by passing through the previous stitch.
Study NCT03740659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
Study NCT03740659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
Study NCT00931931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV1716
Study NCT03766659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MOSE
Description: EUS-FNB with MOSE
Study NCT03766659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ROSE
Description: EUS-FNA with ROSE
Study NCT02434770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioFarma Bivalent Oral Poliomyelitis Vaccine
Description: Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
Study NCT03196752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngeal handshake
Description: palpate for the cricothyroid membrane using the laryngeal handshake technique
Study NCT03196752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simple palpation
Description: conventional
Study NCT02170246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT01451424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: vaginal suppository, daily, for 12 weeks
Study NCT02920983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: contact lens
Study NCT02920983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A II 2
Description: contact lens
Study NCT02920983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A ll 2
Description: contact lens
Study NCT03053895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSDH - Bedside twist drill technique
Description: For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
Study NCT03053895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSDH - Operating Room Burr-hole technique
Description: For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
Study NCT03851016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Story Book
Description: Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
Study NCT03851016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Three weeks of Usual Care with no visits from research team
Study NCT04269603 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Take blood (TA-8V (Stago®)
Description: Healthy volunteers will have 3 blood samples at M0, M3 and M6.
Study NCT00963690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloSys Hemostatic Device (HD)
Description: Deploy CloSys HD to achieve hemostasis
Study NCT00963690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard compression
Description: Use standard compression to achieve hemostasis
Study NCT00963690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard compression
Description: Use standard compression to achieve hemostasis
Study NCT02831270 — intervention group
Intervention type: PROCEDURE
Intervention: Acute normovolemic hemodilution (ANH)
Study NCT02831270 — intervention group
Intervention type: DRUG
Intervention: hydroxyethyl starch (HES 130/0.6)
Study NCT01384084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POP repair plus mini-sling
Description: For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh.
Study NCT01384084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POP repair
Description: For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
Study NCT02696356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRN-1201
Description: GRN-1201 is a vaccine comprised of 4 peptides
Study NCT02696356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GRN-1201
Description: GRN-1201 is a vaccine comprised of 4 peptides
Study NCT04568252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband with millimeter wave emission.
Description: Wristband treatment with millimeter wave emission twice a day for 3 months.
Study NCT04568252 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo of wristband with millimeter wave emission.
Description: Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
Study NCT03640065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: freeze-dried probiotic sachets
Description: * The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants.
Study NCT03640065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fermented dairy product ( yogurt)
Description: * The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home
Study NCT03553316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101-002
Description: -(Single) PK101-002
Study NCT03553316 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PK101
Description: -(Combination) PK101-001, PK101-002
Study NCT00960518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir
Description: adefovir at 10 mg daily for 48 weeks
Study NCT00960518 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TACE
Description: An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
Study NCT04380857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone ophthalmic insert 0.4 mg
Description: intracanalicular dexamethasone insert
Study NCT04380857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone Acetate Ophthalmic Drops
Description: Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue
Study NCT04270825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT with IPT
Description: Group treatment designed to target relationships with both possessions and people.
Study NCT00990483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D mammograpgy system
Description: In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
Study NCT00569686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lovaza
Description: lovaza 4 gm po daily
Study NCT00569686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03811730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Description: Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
Study NCT03811730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Description: Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
Study NCT01126164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Handbook and Peer Basics
Description: Parent and Peer delivered interventions
Study NCT03538340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural
Description: The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
Study NCT03538340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural
Description: The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
Study NCT03538340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intercostal Cryoanalgesia
Description: The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
Study NCT01826162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetate or placebo infusion
Study NCT00976534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 90 mg, capsules, oral, during 3 weeks
Study NCT00976534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, oral, during 3 weeks
Study NCT00931307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A contact lens
Description: Silicone hydrogel, spherical, soft contact lens
Study NCT04196166 — intervention group
Intervention type: OTHER
Intervention: preoperative blood tests
Study NCT06054048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients.
Study NCT01740583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous annuloplasty
Description: plication of the mitral valve annulus
Study NCT00808600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: resource-activating behavioural training programme
Description: Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report.
Study NCT04626375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bioarginine
Description: In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Study NCT02203604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study NCT02203604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study NCT02203604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01734109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantum Negative Pressure Wound Therapy Device
Description: To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
Study NCT02182726 — intervention group
Intervention type: DRUG
Intervention: MOBEC
Study NCT03641235 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sputum collection
Description: Analysis of Sputum collection
Study NCT03771391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU Sphere
Description: PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
Study NCT02439593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy (CTRT)
Description: CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
Study NCT02439593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermochemoradiotherapy (CTRTHT)
Description: Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
Study NCT04089657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib 500mg qd, oral, taken half an hour after a meal
Study NCT04089657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg intravenously on day 1
Study NCT04121091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Pill
Description: Add-on pramipexole
Study NCT01831297 — intervention group
Intervention type: DEVICE
Intervention: measurement of blood pressure
Description: measurement of pulse wave velocity
Study NCT01396252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, 0.5 mg, Once daily, 14 days
Study NCT01396252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, 1 mg, Once daily, 14 days
Study NCT01396252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, 2 mg, Once daily, 14 days
Study NCT01396252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-820836
Description: Tablets, Oral, 0 mg, Once daily, 14 days
Study NCT01396252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
Study NCT05785273 — intervention group
Intervention type: DEVICE
Intervention: Pupillometer
Description: 1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
Study NCT04626375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Study NCT03692039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-pro files in rotating motion
Description: An endodontic file that has controlled memory properties
Study NCT03692039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ProTaper Next files in rotating motion
Description: An endodontic file that has an off center mass of rotation
Study NCT00740207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VISIPAQUE 270
Description: VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
Study NCT00740207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 250
Description: ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution